Claude (Anthropic) vs GPT-Rosalind (OpenAI)

Which one should you pick? Here's the full breakdown.

Our Pick

Claude (Anthropic)

A
8.5/10

Anthropic's flagship LLM -- Opus 4.7 (launched April 16, 2026) with 1M-token context, high-res vision, new xhigh reasoning level, and the most natural conversational style

GPT-Rosalind (OpenAI)

C
6.8/10

OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Launched 2026-04-16 as a Trusted Access research preview. Launch partners: Amgen, Moderna, Allen Institute, Thermo Fisher. Paired with a Life Sciences Codex plugin (50+ scientific tool integrations)

CategoryClaude (Anthropic)GPT-Rosalind (OpenAI)
Ease of Use9.03.0
Output Quality9.09.0
Value8.07.0
Features8.08.0
Overall8.56.8

Pricing Comparison

FeatureClaude (Anthropic)GPT-Rosalind (OpenAI)
Free TierYesNo
Starting Price$0Invite only

Benchmark Head-to-Head

Claude Opus 4.7 (4.6 baseline scores shown; 4.7 announced 13% coding lift, 3x production task completion) benchmarks — GPT-Rosalind (OpenAI) has no published benchmarks

BenchmarkScore
MMLU91.3%
GPQA Diamond91.3%
AIME 202499.8%
HumanEval94%
SWE-bench80.8%
ARC-AGI75.2%

Which Should You Pick?

Pick Claude (Anthropic) if...

  • Easier to use (9 vs 3)
  • Better value for money (8/10)
  • Has a free tier

Writers, analysts, developers, and anyone who values quality of output over quantity of features. If you care about how good the actual text is, Claude is the best.

Visit Claude (Anthropic)

Pick GPT-Rosalind (OpenAI) if...

Researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get Trusted Access. Also relevant to anyone building life-sciences AI products who needs to understand where OpenAI's vertical strategy is heading.

Visit GPT-Rosalind (OpenAI)

Our Verdict

Claude (Anthropic) is the clear winner here with 8.5/10 vs 6.8/10. GPT-Rosalind (OpenAI) isn't bad, but Claude (Anthropic) outperforms it across the board. Pick GPT-Rosalind (OpenAI) only if researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access.